ビジネス · 2023/3/31 分で読めます
Prospective Grant of an Exclusive Patent License: The Development of a CD276 Antibody-Drug Conjugate (ADC) for the Treatment of Solid Tumors
ローカル自動翻訳 · 情報源の原言語
概要
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to BrickBio, Inc. ("BrickBio") located in Woburn, Massachusetts.